PNA-peptide conjugates as intracellular gene control agents

Area of Science:

• Molecular Biology
• Biochemistry
• Gene Therapy

Background:

• Aberrant splicing of the beta-globin gene can lead to genetic disorders.
• MicroRNAs play crucial roles in gene regulation, and their dysregulation is implicated in various diseases.
• Current gene therapy and nucleic acid-based treatments often rely on transfection agents, which can have limitations.

Purpose of the Study:

• To evaluate the efficacy of serum-stabilized PNA-internalization peptides (Pip) in correcting aberrant beta-globin splicing.
• To assess the ability of PNA-Pip conjugates to inhibit microRNA-122 in liver cells.
• To determine if these PNA-based strategies can function effectively without the need for transfection agents.

Main Methods:

• Conjugation of PNA complementary to the 705 aberrant beta-globin splice site to PNA-internalization peptides (Pip).
• Treatment of Hela pLuc705 cells with PNA-Pip conjugates to assess splicing correction and luciferase production.
• Treatment of liver cells with PNA conjugated to lysine residues to inhibit microRNA-122.

Main Results:

• PNA-Pip conjugates corrected aberrant beta-globin splicing and increased luciferase production in Hela pLuc705 cells with sub-micromolar EC50 values.
• The PNA-based approach demonstrated efficacy in the absence of any transfection agent.
• Inhibition of microRNA-122 in liver cells was achieved using PNA with attached lysine residues, also without a transfection agent.

Conclusions:

• Serum-stabilized PNA-Pip conjugates offer a promising, transfection-agent-free method for correcting aberrant gene splicing.
• PNA-based molecules can effectively inhibit microRNAs in liver cells without requiring transfection agents.
• These findings highlight the potential of PNA-based therapeutics for genetic disorders and microRNA-related conditions.